Henry Meds review

Henry Meds: a flat, established price — with an exit clause worth reading first

Henry publishes injectable semaglutide at $297 per month on its legal programs page, including medication and injection supplies. Paid-in-full plans reduce the monthly equivalent to $247 for six months or $197 for twelve months. Tirzepatide is currently itemized as an oral supply: the section labeled three months lists $891 paid in full, but its delivery text conflicts on duration. Confirm the exact supply and any injectable option before paying.

The six-month injectable semaglutide plan is $1,482 paid in full, compared with $1,782 at six payments of $297. The twelve-month paid-in-full total is $2,364, compared with $3,564 at the monthly price. Those savings come from a larger commitment, not a different one-month checkout price. Keep oral programs separate: the legal page also lists a $249 semaglutide tablet program and a lower-dose sublingual tablet or drop program at $179. The general GLP-1 headline starting at $179 therefore does not describe injectable semaglutide. Ask which route, supply quantity, payment schedule and cancellation obligation the offered plan actually includes.

An async option, where a mother's state allows it

Henry's own site states the process directly: a member can schedule a face-to-face video call with a provider, or, depending on their home state, choose an independent provider review without a video call. That is a genuine accommodation for a mother trying to avoid a fixed appointment slot, and it's worth confirming during the free eligibility check rather than assuming either way — the option is state-dependent, not universal.

The clause to read before a multi-month plan

Henry's own cancellation terms include a detail worth flagging plainly: a member on a multi-month plan may be required to pay out the remaining balance to cancel, unless a healthcare provider determines the member is unable to continue for medical reasons. That is not unusual for a prepaid structure, but it is the opposite of the pause-anytime flexibility a mother's changing circumstances — a pregnancy, a nursing stretch, a budget shock — often require. Read the specific terms of whichever plan length is offered before committing to more than a single month.

What the flat model does not offer

Henry publishes no postpartum, breastfeeding, or PCOS-specific guidance. As with every GLP-1, the medication is not established as safe for use during pregnancy or breastfeeding, and Henry's own materials do not walk a mother through that timing question the way a program built around it would. The flat-fee simplicity is real; the maternal framing is not present, and a mother whose central question is sequencing a GLP-1 around a pregnancy or a nursing window should expect to bring that conversation to the provider herself.

The bottom line

Henry offers monthly and longer commitments, with different prices by treatment, route and plan length. Its public programs page now makes injectable semaglutide pricing readable, but the oral tirzepatide duration needs clarification. Read the remaining-balance cancellation clause before choosing a multi-month plan.